Literature DB >> 27251172

Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes.

Pauline Radreau1, Marine Porcherot1, Christophe Ramière2, Karim Mouzannar1, Vincent Lotteau1, Patrice André3.   

Abstract

Hepatitis B virus (HBV) and bile salt metabolism seem tightly connected. HBV enters hepatocytes by binding to sodium taurocholate cotransporting polypeptide (NTCP), the genome of which contains 2 active farnesoid X receptor (FXR) α response elements that participate in HBV transcriptional activity. We investigated in differentiated HepaRG cells and in primary human hepatocytes (PHHs) effects of FXR activation on HBV replication and of infection on the FXR pathway. In HepaRG cells, FXR agonists (6-ethyl chenodeoxycholic acid and GW4064), but no antagonist, and an FXR-unrelated bile salt inhibited viral mRNA, DNA, and protein production (IC50, 0.1-0.5 μM) and reduced covalently closed circular DNA pool size. These effects were independent of the NTCP inhibitor cyclosporine-A, which suggests inhibition occurred at a postentry step. Similar results were obtained in PHHs with GW4064. Infection of these cells increased expression of FXR and modified expression of FXR-regulated genes SHP, APOA1, NTCP, CYP7A1, and CYP8B1 with a more pronounced effect in PHHs than in HepaRG cells. FXR agonists reversed all but one of the HBV-induced FXR gene profile modifications. HBV replication and FXR regulation seem to be interdependent, and altered bile salt metabolism homeostasis might contribute to the persistence of HBV infection.-Radreau, P., Porcherot, M., Ramière, C., Mouzannar, K., Lotteau, V., André, P. Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. © FASEB.

Entities:  

Keywords:  FXR agonist; bile salt; cccDNA; nuclear receptor

Mesh:

Substances:

Year:  2016        PMID: 27251172     DOI: 10.1096/fj.201500134

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis.

Authors:  Tongyao Wang; Xingyu Rong; Chao Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

Review 2.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 3.  In Vivo Model Systems for Hepatitis B Virus Research.

Authors:  Ana Maria Ortega-Prieto; Catherine Cherry; Harry Gunn; Marcus Dorner
Journal:  ACS Infect Dis       Date:  2019-01-08       Impact factor: 5.084

4.  Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.

Authors:  Robin Erken; Patrice Andre; Elise Roy; Neeltje Kootstra; Noelie Barzic; Hugo Girma; Christian Laveille; Pauline Radreau-Pierini; Raphael Darteil; Jacky Vonderscher; Pietro Scalfaro; Pisit Tangkijvanich; Robert Flisiak; Henk Reesink
Journal:  J Viral Hepat       Date:  2021-09-29       Impact factor: 3.517

5.  Moving Fast Toward Hepatitis B Virus Elimination.

Authors:  Leda Bassit; Suzane Kioko Ono; Raymond F Schinazi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Fexaramine as an entry blocker for feline caliciviruses.

Authors:  Yunjeong Kim; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2018-02-15       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.